Location

Rochester, Minnesota

Contact

Baughn.Linda@mayo.edu

SUMMARY

Linda B. Baughn, Ph.D., has a broad research background in immunology and cancer biology with a focused interest in hematologic malignancies, specifically multiple myeloma (MM). In addition to her role as a co-director of the Clinical Genomics Laboratory and board-certified clinical laboratory cancer geneticist, she has been actively engaged in MM translational research since 2004.

MM is a devastating and incurable malignancy of plasma cells that currently has no cure. Although significant improvements in the treatment of patients with MM have resulted in increased survival, nearly all patients eventually become refractory to these treatments and succumb to the disease. Dr. Baughn's research and clinical interests are aimed in advancing the diagnosis and prognosis of all patients with MM.

Focus areas

  • Improved clinical diagnostic approaches for multiple myeloma. Utilization of next-generation sequencing techniques, specifically mate-pair sequencing, in the characterization of genomic abnormalities such as structural and copy number abnormalities in patients with hematologic malignancies including MM.
  • Understanding multiple myeloma drug resistance. Identification of novel biomarkers of drug sensitive and resistant MM cells using genetic models and multiparameter time of flight mass cytometry (CyTOF). CyTOF phenotypically characterizes MM cell lines and primary MM cells using numerous antibody combinations to identify rare subpopulations and appreciate clonal heterogeneity.
  • Health disparity research. African Americans are two to three times more likely to develop MM. It is important to elucidate the genetic mechanisms of this racial disparity. Dr. Baughn and colleagues have utilized genotyping data from single nucleotide polymorphisms that are ancestrally informative to calculate individual ancestry as a novel approach rather than relying only on self-report ancestry to understand health disparities of MM.

Significance to patient care

Multiple myeloma remains an incurable plasma cell malignancy with about 30,000 new diagnoses and approximately 12,000 deaths annually in the U.S. In addition, MM has one of the most pronounced disparities in the incidence between African Americans and European Americans. Dr. Baughn's research efforts are aimed to understand this racial disparity and also identify novel ways that genomic abnormalities and biomarkers of drug resistance in MM can be identified.

Clinical Studies

See my clinical studies

PUBLICATIONS

See my publications

PROFESSIONAL DETAILS

Primary Appointment

  1. Consultant, Division of Laboratory Genetics and Genomics, Department of Laboratory Medicine and Pathology

Joint Appointment

  1. Consultant, Department of Clinical Genomics, Mayo Clinic Enterprise

Academic Rank

  1. Associate Professor of Laboratory Medicine And Pathology

EDUCATION

  1. Clinical Fellowship - Mentor: Bharat Thyagarajan, MD, PhD Department of Laboratory Medicine and Pathology, University of Minnesota
  2. Clinical Fellowship - Mentor: Betsy Hirsch, PhD Department of Laboratory Medicine and Pathology, University of Minnesota
  3. Post Doctoral Fellowship - Mentor: Matthew Scharff, MD. Research Topic: Targeting of somatic hypermutation in B cells Department of Cell Biology, Albert Einstein College of Medicine
  4. Post Doctoral Fellowship - Mentor: Selina Chen-Kiang, PhD. Research Topic: Identified the use of the cell cycle inhibitor, PD 0332991, to prevent multiple myeloma tumor growth Cornell University, Weill Cornell Medical College
  5. Graduate School - Mentor: Naomi Rosenberg, PhD. Research Topic: Abelson murine leukemia virus pre-B cell transformation Tufts University
  6. Ph.D. - Immunology Tufts University
  7. Undergraduate Research Fellow - Advisor: Michael W. Crowder, PhD. Research Topic: Performed studies of metallo-beta-lactamase L1 from Stenotrophomonas maltophilia. Department of Chemistry and Biochemistry, Miami University
  8. BS - Chemistry Miami University
  9. Undergraduate Research Fellow - Advisor: Yen-Ho Chu, Ph.D. Research: Studied Vancomycin resistance. The Ohio State University, Department of Chemistry
.
BIO-20473938

Mayo Clinic Footer